Mean (95% CI) changes in lung function and induced sputum eosinophil counts during each treatment period
| Placebo | Fluticasone | p value | |
|---|---|---|---|
| PEF=peak expiratory flow; FEV1=forced expiratory volume in 1 second; PC20=concentration of methacholine provoking a fall in FEV1 of 20% or more. | |||
| *Median values. | |||
| p values relate to comparison between placebo and fluticasone propionate for magnitude of change. | |||
| Non-smokers | |||
| PEF (l/min) | |||
| Morning | +14 (−2.4 to 30.7) | +27 (14.4 to 39.6) | 0.016 |
| Evening | +2 (−11.8 to 17.2) | +16 (2.7 to 29.5) | 0.051 |
| FEV1 (l) | −0.05 (−0.18 to 0.07) | +0.17 (0.04 to 0.31) | 0.01 |
| FEV1 (%) | −1 (−4.3 to 2.2) | +5 (0.9 to 8.5) | 0.02 |
| Geometric mean methacholine PC20 (mg/ml) | −0.07 (−0.7 to 0.9) | +1.3 (0.3 to 6.3) | 0.0002 |
| % sputum eosinophils* | 0 (−0.7 to 2.5) | −1.8 (−6.6 to 2.5) | 0.05 |
| Smokers | |||
| PEF (l/min) | |||
| Morning | 0 (−8.5 to 9.0) | −5 (−17.7 to 7.8) | NS |
| Evening | 1 (−16.5 to 19.4) | 0 (−8.5 to 9.0) | NS |
| FEV1 (l) | −0.02 (−0.18 to 0.13) | −0.06 (−0.23 to 0.11) | NS |
| FEV1 (%) | −1 (−5.7 to 4.7) | −1 (−5.8 to 3.6) | NS |
| Geometric mean methacholine PC20 (mg/ml) | −0.3 (−2.4 to 2.3) | −0.3 (−1.5 to 6.1) | NS |
| % sputum eosinophils* | 0 (−0.5 to 1.4) | 0 (−2.9 to 5.7) | NS |